• Home
  • Search Results
  • Domains of genome-wide gene expression dysregulation in Down's syndrome.

Domains of genome-wide gene expression dysregulation in Down's syndrome.

Nature (2014-04-18)
Audrey Letourneau, Federico A Santoni, Ximena Bonilla, M Reza Sailani, David Gonzalez, Jop Kind, Claire Chevalier, Robert Thurman, Richard S Sandstrom, Youssef Hibaoui, Marco Garieri, Konstantin Popadin, Emilie Falconnet, Maryline Gagnebin, Corinne Gehrig, Anne Vannier, Michel Guipponi, Laurent Farinelli, Daniel Robyr, Eugenia Migliavacca, Christelle Borel, Samuel Deutsch, Anis Feki, John A Stamatoyannopoulos, Yann Herault, Bas van Steensel, Roderic Guigo, Stylianos E Antonarakis

Trisomy 21 is the most frequent genetic cause of cognitive impairment. To assess the perturbations of gene expression in trisomy 21, and to eliminate the noise of genomic variability, we studied the transcriptome of fetal fibroblasts from a pair of monozygotic twins discordant for trisomy 21. Here we show that the differential expression between the twins is organized in domains along all chromosomes that are either upregulated or downregulated. These gene expression dysregulation domains (GEDDs) can be defined by the expression level of their gene content, and are well conserved in induced pluripotent stem cells derived from the twins' fibroblasts. Comparison of the transcriptome of the Ts65Dn mouse model of Down's syndrome and normal littermate mouse fibroblasts also showed GEDDs along the mouse chromosomes that were syntenic in human. The GEDDs correlate with the lamina-associated (LADs) and replication domains of mammalian cells. The overall position of LADs was not altered in trisomic cells; however, the H3K4me3 profile of the trisomic fibroblasts was modified and accurately followed the GEDD pattern. These results indicate that the nuclear compartments of trisomic cells undergo modifications of the chromatin environment influencing the overall transcriptome, and that GEDDs may therefore contribute to some trisomy 21 phenotypes.

Product Number
Product Description

L-Lysine, crystallized, ≥98.0% (NT)
L-Lysine acetate salt, ≥98% (HPLC)
L-Lysine, ≥98% (TLC)
Lysine hydrochloride, European Pharmacopoeia (EP) Reference Standard
L-Lysine, analytical standard
Lysine acetate, European Pharmacopoeia (EP) Reference Standard
L-Lysine monohydrochloride, SAJ special grade, ≥99.0%
L-Lysine monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
L-Lysine monohydrochloride, BioUltra, ≥99.5% (AT)
L-Lysine monohydrochloride, certified reference material, TraceCERT®
L-Lysine monohydrochloride, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
L-Lysine monohydrochloride, reagent grade, ≥98% (HPLC)
L-Lysine Acetate, Pharmaceutical Secondary Standard; Certified Reference Material